

2021_Cefazolin.pdf

by

Submission date: 13-Mar-2023 10:53PM (UTC+0700)

Submission ID: 2036243440

File name: 2021_Cefazolin.pdf (2.11M)

Word count: 7597

Character count: 38727



Data Article

Validation of spectrophotometric method for quantification of cefazoline in simulated tear fluid and porcine ocular tissue from thermosensitive-mucoadhesive *in situ* ocular gel preparation

Alhidayah^a, Muh. Al Fiqri^a, Nirmayanti^a, Ummu Athiyyah^a,
 Tamara Gabriela Angeleve Fadjjar^b, Firzan Nainu^a, Andi Arjuna^a,
 Andi Dian Permana^{a,*}

^a Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia

^b Faculty of Medicine, Hasanuddin University, Makassar, 90245, Indonesia



ARTICLE INFO

Keywords:

Cefazoline
 UV-Vis spectrophotometry
 bioanalysis in ocular tissue
 validation
in situ gel

ABSTRACT

In the formulation development, it is necessary to validate the analytical method as a critical step. Here, we validated the spectrophotometric method of cefazoline (CFZ) from thermosensitive-mucoadhesive *in situ* in simulated tear fluid (STF) and ocular tissue for *in vitro* and *ex vivo* studies, respectively. The method was validated as per ICH guidelines, showing excellent linearity with the correlation coefficient values of 0.9997 in STF and 0.9981 in ocular tissue with acceptable precision and accuracy. The L_{50} values were 0.496 $\mu\text{g/mL}$ and 2.390 $\mu\text{g/mL}$ in STF and ocular tissue, respectively. Moreover, LOQ values were 1.504 $\mu\text{g/mL}$ in STF and 7.242 $\mu\text{g/mL}$ in ocular tissue. The method was utilized in the *in vitro* and *ex vivo* studies, showing that the concentration of CFZ localized in the ocular tissue was significantly improved following its incorporation into thermosensitive mucoadhesive *in situ* gels. *In vivo* studies with suitable analytical method must be performed.

1. Rationale

Specifications Table

| | |
|-------------------------|--|
| Subject area | Spectroscopy, Analytical Method Validation |
| Compounds | Cefazoline |
| Data category | Spectral, <i>in vitro</i> release, <i>ex vivo</i> delivery, drug concentration |
| Data acquisition format | UV-Vis Spectrum |
| Data type | Analyzed |
| Procedure | We developed and validated the spectrophotometric method of CFZ in simulated tear fluid (STF) and ocular tissue for <i>in vitro</i> and <i>ex vivo</i> studies, respectively. The method was successfully validated as per the ICH guidelines. |
| Data accessibility | Data is with this article |

25

* Corresponding author at: Faculty of Pharmacy, Hasanuddin University, Indonesia.
 E-mail address: andi.dian.permana@farmasi.unhas.ac.id (A.D. Permana).

<https://doi.org/10.1016/j.cdc.2021.100793>

Received 23 September 2021; Received in revised form 12 October 2021; Accepted 3 November 2021

Available online 8 November 2021

2405-8300/© 2021 Elsevier B.V. All rights reserved.

67

Bacterial keratitis is a potentially blinding corneal infection and has been categorized as a neglected tropical disease. Prior to blindness, there are several important signs and symptoms associated with the disease, including acute ocular pain, decreased vision, corneal ulceration, and infiltrates in the anterior chamber [1]. Several studies around the world have consistently reported Gram-positive bacteria as the most common etiology of this infection [2,3]. Several risk factors have been identified, including contact lens use, trauma, ocular surface and eyelid diseases, post ocular surgery, use of topical steroids, and systemic immunosuppression [3]. The pathogenesis associated with each risk factor occurs in a complex and multifactorial manner that begins with the accumulation and attachment of microbes to the corneal surface. For example, the use of contact lenses as a risk factor most often occurs due to impaired tear exchange, resulting in stagnation under the contact lens hence facilitating the adherence and accumulation of commensal bacteria at a later timepoint [4].

Topical antibiotic has become the first line in the treatment of bacterial keratitis [5]. Cefazolin (CFZ) is a first-generation cephalosporin antimicrobial used for keratitis infections therapy by inhibiting bacterial [50] wall synthesis. CFZ is available in eye drop preparations with a dose of 3,5 mg/mL [6]. However, when applied *via* ocular route, only 5% of the applied drug could penetrate the ocular tissue due to short contact of the preparations in the ocular tissue [7]. Additionally, many drug companies promote drugs at a scale 50 μ L as the maximum volume for the application of eye drops. However, generally, 20 μ L of these eye drops do not touch the eye surface, and only 30 μ L remains on the ocular surface area. Thus, the application of eye drop preparations is not optimal due to the excessive application volume required. Consequently, various new drug delivery systems have been created to overcome these issues. For example, structural changes of pharmaceutical preparations from liquid to gel in an *in situ* condition, well-known as thermosensitive *in situ* gel, has attracted the attention of researchers to employ this approach to increase the retention time of drugs on the surface of the eye [8]. Several studies have shown that the formulation of active substances in thermosensitive preparations was able to improve the concentration of drugs in the ocular tissue [8,9]. In addition, the presence of mucosa in the ocular tissue could improve the ocular contact [53] by using the mucoadhesive system [8]. Accordingly, the combination of thermosensitive and mucoadhesive could be an alternative approach to deliver CFZ to the ocular tissue for keratitis treatment.

In the formulation development, *in vitro* and *ex vivo* assessments shall be conducted before performing *in vivo* evaluation. *In vitro* study is used to predict the release manner of the formulated drugs. Importantly, in ocular delivery studies, *ex vivo* is performed by using corneal tissue of animals to mimic the *in vivo* conditions [10]. By performing the *ex vivo* studies, some formulations might be eliminated from the *in vivo* studies and, thus, could minimize the use of animals in the *in vivo* studies. In the *in vitro* and *ex vivo* evaluation, analytical methods to quantify active substances should be developed and validated. Analytical procedures allowing the precise determination of drugs in the development studies is crucial. Essentially, analytical validation procedures must be in place to ensure reliability, traceability [49] or comparability of results. Thus, developing and validating the analysis procedure to determine the amount of cefazolin in the *in vitro* and *ex vivo* studies is the important steps for the development of new dosage forms [11].

In terms of the analytical method, several techniques have been developed to quantify CFZ, including high-performance liquid chromatography and mass spectroscopy. Alternatively, the UV-Vis spectrophotometry method is usually preferable with its advantages. Analytical methods other than UV-Vis spectrophotometry are expensive, in contrast to the UV-Vis spectrophotometry method which has the advantages of being time-efficient, economical, widely available, easy and simple to use, relatively accurate, and results are obtained satisfactory. Essentially, no residue is produced when the analysis uses reagents or solvents [12,13]. Spectrophotometry is a method used mainly in routine analysis or research for identification. Additionally, in the developing countries, spectrophotometric method could potentially be a great favor to be applied. Several studies have shown the effectiveness of the spectrophotometry method to quantify several drugs in the biological matrices [14–16]. Furthermore, the spectrophotometry method has also been applied to quantify drugs in fruits, food and beverages products [17–19]. Accordingly, this has shown that despite its simplicity, this method has been reported to be effective in the several analytical purposes. Therefore, in this study, as part of the formulation development process, we validated the method for the quantification of CFZ in thermosensitive-mucoadhesive ocular preparation. The validated method was utilized to analyze the drug content in the formulation, *in vitro* permeation, *ex vivo* permeation and *ex vivo* retention in the ocular tissues.

2. Procedure

2.1. Material

Cefazolin sodium salt (CFZ) (purity 89.1–110.1%) was obtained from Sigma Aldrich Pte Ltd. (Singapore, Singapore). Pluronic® F127 and F68 were kindly provided by BASF Indonesia (Jakarta, Indonesia). Sodium chloride (NaCl). Sodium bicarbonate (NaHCO_3) and calcium chloride dihydrate ($\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$) were obtained from Merck (Jakarta, Indonesia). Other materials were analytical grade.

2.2. Preparation of stock solution

Simulated tear fluid (STF) was prepared by dissolving 6.7 g NaCl, 2.0 g NaHCO_3 and 0.08 g $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ in 1 L deionized water. The final pH was adjusted to 7.4 [20]. CFZ stock solution was prepared by weighing 10 mg of CFZ and put into a 10 mL volumetric flask. STF was added to dissolve the CFZ and then made up to the mark to obtain a final concentration of 1000 $\mu\text{g}/\text{mL}$.

2.3. Determination of maximum wavelength

250 μL of the stock solution of CFZ was transferred into a volumetric flask prior to dilution with STF for up to 10 mL (concentration

25 µg/ml). The absorbance of the solution was measured at a wavelength of 200–400 nm using a UV-Vis spectrophotometer (HALO XB-10, Dynamica Scientific Ltd. United Kingdom). The maximum wavelength was determined from the absorption in the sample.

17

2.4. Preparation calibration standards and quality control samples

In this study, calibration standards and quality control samples were prepared in two different matrices, namely STF and porcine ocular tissue. STF was used in the drug content in the formulation, *in vitro* permeation and *ex vivo* permeation studies. Porcine ocular tissue was used in the *ex vivo* retention in the ocular tissues.

For STF, the stock solution was diluted with STF to obtain a calibration standard solution with a concentration from 0.625 to 20 µg/mL. Then, quality control samples were prepared by diluting CFZ stock solution using STF to achieve low quality control (LQC) concentration (2 µg/mL), medium quality control (MQC) concentration (10 µg/mL), and high quality control (HQC) concentration (15 µg/mL).

To prepare porcine tissue matrices, initially, the tissue was crushed, then added to distilled water in a ratio of 9:1. This mixture was then homogenized for 10 min. After obtaining the tissue matrices, a series concentration (40 – 1.25 g/mL) were made by spiking the stock solution to the tissue matrices [21]. Afterwards, the LQC (10 µg/mL), MQC (20 µg/mL), and HQC (30 µg/mL) of CFZ in tissue matrices were also prepared in a similar fashion.

2.5. Sample preparation and extraction of cfz from ocular tissues

For quantification of CFZ in the ocular tissue for the *ex vivo* studies, sample extractions using two organic solvents, methanol and acetonitrile, were carried out [22,23]. In this study, 1 g of tissue spiked CFZ was used. To optimize the extraction process, several volumes of each solvent 1 mL, 3 mL, 5 mL and 7 mL, were used. Briefly, the solvent was mixed with the tissue and vortexed for 10 min. Following this step, the mixture was centrifuged at 7000 rpm for 15 min (LC-04S Centrifuge, Zenlab (Jiangsu) Co., LTD. China). The supernatant was collected and the organic solvent was evaporated in a fume hood. Afterwards, 1 mL of STF was added into the dry extract and vortexed for 5 min. The samples were then centrifuged at 7000 rpm for 15 min and the clear supernatant was measured using spectrophotometric.

2.6. Preparation of cfz thermosensitive-mucoadhesive gel

CFZ thermosensitive-mucoadhesive gel was prepared using the cold method by dispersing a combination of Pluronic® F127 16% and Pluronic® F68 4% w/w in cold distilled water (at 4 °C) and maintained under constant stirring to form poloxamer solution and then kept in the refrigerator overnight until a clear solution was observed. Hyaluronic acid 0.2% w/w was dissolved in hot water until a clear solution was formed and dissolved in poloxamer solution. CFZ 0.35% was dissolved in distilled water and dissolved in poloxamer solution. Benzalkonium chloride 0.01% was added to the poloxamer solution and stirred until a clear solution was formed [24].

13

2.7. Method validation

2.7.1. Specificity

In an attempt to perform the specificity test, CFZ solution in gel formulation, blank gel formulation, CFZ in ocular tissue matrices and blank ocular tissue matrices were used. All samples were scanned using spectrophotometry UV-Vis at the wavelength between 200 nm and 400 nm. Specificity was evaluated by observing the peak of CFZ in each sample.

2.7.1. Linearity, LOD and LOQ

The correlation coefficient values of the calibration curves obtained from STF and ocular tissue were used as a parameter for linearity. Furthermore, the calibration curve was also used to calculate limit of detection (LOD) and limit of quantification (LOQ) using the following equation [25]:

$$\text{LOD} = \frac{3.3 \sigma}{S} \quad (1)$$

$$\text{LOQ} = \frac{10 \sigma}{S} \quad (2)$$

Where σ = the SD of the response of the data and S = the slope of the calibration curve.

2.7.2. Accuracy and precision

Accuracy and precision were determined in intra-day and inter-day measurements. Intra-day was measured three times in a day, while inter-day was measured three days in a row. After the measurement for intra-day and inter-day the relative standard deviation (RSD,%) and relative errors (RE,%) were calculated to interpret the values of accuracy and precision, respectively. LOQ, LQC, MQC, and HQC were used in this method, where the values should be $\pm 15\%$ [26].

2.7.3. Determination of extraction recovery

The extraction recovery was obtained by comparing the measured value of matrix concentrations with the extracts of the blank matrices with equivalent analyte [27].

2.7.4. Dilution integrity

The effect of sample dilution should be determined during the validation of the quantitative method. To perform this, CFZ was prepared in the concentrations of 75 µg/mL in STF and 200 µg/mL in ocular tissue. Each sample was diluted 5 times and 10 times, and the RSD and RE values were then calculated.

2.8. Application of the method

2.8.1. Determination of drug content

The thermosensitive-mucoadhesive gel was weighed accurately and diluted with STF to obtain a final concentration of 10 µg/ml and tested for drug content using a UV-Vis spectrophotometer. In this study, the result of the drug content formula was also compared with the result of 10 µg/ml CFZ solution [28].

2.8.2. In vitro, ex vivo permeation and ex vivo retention study of CFZ from thermosensitive-mucoadhesive gel

In this study, both *in vitro* and *ex vivo* evaluations were carried out using Franz cell diffusion, where the difference between the two methods was the membranes used. The *in vitro* test used a dialysis membrane (Spectra-Por®, 12,000 - 14,000 MWCO dialysis membrane) [29], while the *ex vivo* test used porcine cornea tissue [30]. Prior to the experiment, 24 mL of STF was filled in the inside receiver compartment of the Franz cell diffusion, then stirred at 100 rpm and accurately maintained the temperature at 37 °C.

After the pretreatment steps, the formulation was weighed accurately equal to 10 mg of CFZ. The sample was put above the membrane and covered with the top part of Franz cell diffusion. The diffusion area of the Franz diffusion cell was 4.9 cm². For every certain time span, 1 ml was sampled from the cell diffusion arm, and 1 ml of fresh STF was added again. Sampling was carried out at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, and 24 h. The absorbances of samples were measured using spectrophotometry with an appropriate dilution.

Following the *ex vivo* permeation study, after 1 h, 6 h and 24 h, the ocular tissue was removed from the cell diffusion, and the excess of the formulation was removed. The extraction solvent was mixed with the ocular tissue using the optimized volume obtained from the method described in Section 2.5. The mixture was vortexed for 10 min and centrifuged for 15 min at 7000 rpm. The clear supernatant was dried under a fume hood at 25 °C and the dry extract was reconstituted using 1 mL of STF. The mixture was vortexed for 5 min and centrifuged for 15 min at 7000 rpm. CFZ in the supernatant was measured using spectrophotometry. In both *in vitro* and *ex vivo* studies, CFZ solution was used as a control.

The release kinetic profile was calculated using the following equations [31]

$$\text{Zero Order Kinetics : } C_t = C_0 + k_0 t \quad (3)$$

$$\text{First Order Kinetics : } \ln C_t = \ln C_0 + k_1 t \quad (4)$$

$$\text{Higuchi Model : } C_t = k_H \sqrt{t} \quad (5)$$

$$\text{Korsmeyer - Peppas Model : } C_t = k_{KP} t^n \quad (6)$$

$$\text{Hixson - Crowell Model : } C_t^{1/3} = C_0^{1/3} k_{HC} t \quad (7)$$

Where C_t is the concentration of cefazoline released at time t , C_0 is the initial amount of CFZ in STF (at $t = 0$), k_0 is constant of zero-order kinetics, k_1 is constant of first-order kinetics, k_H is constant of Higuchi model, k_{KP} is constant of Korsmeyer-Peppas model, and k_{HC} is constant of Hixson-Crowell model.

2.9. Statistical analysis

GraphPad Prism® version 6 (GraphPad Software, San Diego, California, USA) was applied to perform the statistical analysis. p values < 0.05 represent a statistical difference between data analyzed.

3. Data, value and validation

3.1. Determination of maximum wavelength and specificity

As an initial step in the development of formulation, the validation of the analytical method should initially be developed. In this study using UV-Vis spectrophotometry, the maximum wavelength of CFZ in the two matrices used, namely STF and porcine ocular tissue, was firstly determined. As shown in Fig. 1, one spectrum peak in STF was observed at 272 nm, and two spectral peaks at 220 nm and 272 nm were observed from the ocular tissue matrices.

To decide the wavelength used for the analysis process, the specificity test was carried out. In this step, the spectrum of the possible interferences was also observed. Blank thermosensitive formulation and blank tissue were scanned, and it was found that both samples showed peaks around 220 nm (Fig. 2). Therefore, 272 nm was selected as the wavelength used in the further steps.

3.2. Preparation of samples and extraction of CFZ from ocular tissue

To determine the concentration of CFZ localized in the ocular tissue after *ex vivo* studies, the extraction method was screened. The results show that the extraction recoveries when methanol was used were $11.83 \pm 0.78\%$, $37.79 \pm 2.28\%$, $91.44 \pm 0.49\%$ and $93.05 \pm 2.30\%$ for 1 mL, 3 mL, 5 mL and 7 mL of extraction volumes, respectively. On the other hand, $8.81 \pm 0.13\%$, $17.74 \pm 5.20\%$, $33.75 \pm 0.82\%$ and $56.91 \pm 0.90\%$ of extraction recoveries were found when acetonitrile was used with volumes of 1 mL, 3 mL, 5 mL and 7 mL, respectively. It was found that methanol was more effective than acetonitrile. In our study, despite the higher extraction recovery obtained from 7 mL methanol, the recovery obtained from 5 mL was not statistically ($p > 0.05$) different compared to 5 mL. Therefore, 5 mL methanol was selected for further studies.

3.3. Linearity, LOD, and loq

In this evaluation, the calibration curves in STF and ocular tissue were found to be linear, with the correlation coefficient values of 0.9997 and 0.9981, respectively. It has been reported in a previous study that the acceptable linearity of the calibration curve in the analytical validation was ≥ 0.998 [26,32,33]. The curves of calibration solutions of CFZ in STF and ocular tissue are shown in Fig. 3. Moreover, the spectrums of all samples in the calibration solution are depicted in Fig. 4. Generally, the absorbance values of the samples analyzed using spectrophotometer are between 0.2 and 0.8 [34]. However, depending on the instrument used, an absorbance value of < 1 was also found. Several studies have shown that the calibration curves which were not between 0.2 and 0.8 could result in acceptable linearity, and importantly, have been successfully applied to quantify several analytes [15,17]. Accordingly, as the calibration curves found in our study showed the acceptable linearity, the curves could be precisely used in the further validation steps. Furthermore, the LOD and LOQ were determined in STF and ocular tissues. These values were obtained from calibration curves. It was found that the LOD of CFZ in STF and ocular tissue were calculated to be $0.496 \mu\text{g/mL}$ and $2.390 \mu\text{g/mL}$, respectively. Moreover, LOQ values were $1.504 \mu\text{g/mL}$ and $7.242 \mu\text{g/mL}$ in STF and ocular tissue, respectively.

3.4. Accuracy and precision

Accuracy and precision were evaluated in STF and ocular tissue. LOQ, LQC, MQC, and HQC were used for inter-day and intra-day measurements with three replications for each measurement to determine the value of accuracy and precision. After measuring inter-day and intra-day, the relative standard deviation (RSD) and relative error (RE) values were calculated. Where precision was denoted by RSD and accuracy was denoted by RE. For STF, it can be seen in Table 1 that intra-day RSD values were in the range of 1.35% - 12.13%, and RE values were in the range of -3.76% - 9.45%. In Table 2, it can be seen that the accuracy and precision values for inter-day, where the RSD values were in the range of 1.2% - 11.66% and the RE values were in the range of -9.86% - 9.81%.

For ocular tissue matrices, it can be seen in Table 3 that for intra-day, the RSD values were between 1.28% and 8.6%, and the RE values were between -6.76% and 8.16%. While on the inter-day, the RSD values were in the range of 3.43% - 9.52% and the RE values were in the range of -10.98% - 7.79% (Table 4). According to the requirement from ICH [35], supported by several studies reporting that the accuracy and precision values should be $\pm 15\%$ [22,23,36], the analytical method using a spectrophotometer for the determination of CFZ in STF and ocular tissue developed in this study was found to be precise and accurate.




Fig. 1. Maximum UV absorption of CFZ in STF (A) and ocular tissue (B).




Fig. 2. Representative UV-Spectra of CFZ in thermosensitive gel and blank formulation (A) and blank ocular tissue and CFZ solution (B).




Fig. 3. The calibration curve of CFZ in STF (A) and ocular tissue (B).




Fig. 4. Spectrum of CFZ standard solutions in STF (A) and ocular tissue (B).

43

Table 1
Intra-day precision and accuracy data of spectrophotometry for quantification of CFZ in STF ($n = 3$).

| Intra-day Precision and Accuracy | | | | |
|----------------------------------|--|---|------------------|----------------|
| Replication | Concentration added ($\mu\text{g/mL}$) | Concentration found ($\mu\text{g/mL}$) \pm SD | Precision (%RSD) | Accuracy (%RE) |
| 1 | 1.5 | 1.44 \pm 0.13 | 8.82 | -3.76 |
| | 2 | 2.03 \pm 0.25 | 12.13 | 1.45 |
| | 8 | 8.54 \pm 0.18 | 2.14 | 6.76 |
| | 15 | 15.47 \pm 0.73 | 4.72 | 3.12 |
| 2 | 1.5 | 1.61 \pm 0.11 | 7.00 | 7.42 |
| | 2 | 1.96 \pm 0.09 | 4.78 | -1.91 |
| | 8 | 8.72 \pm 0.18 | 2.10 | 9.05 |
| | 15 | 15.32 \pm 0.21 | 1.35 | 2.10 |
| 3 | 1.5 | 1.64 \pm 0.09 | 5.27 | 9.45 |
| | 2 | 1.98 \pm 0.20 | 10.13 | -0.99 |
| | 8 | 8.30 \pm 0.27 | 3.25 | 3.72 |
| | 15 | 15.31 \pm 0.23 | 1.50 | 2.05 |

44

Table 2
Inter-day precision and accuracy data of spectrophotometry for quantification of CFZ in STF ($n = 3$).

| Inter-day Precision and Accuracy | | | | |
|----------------------------------|--|---|------------------|----------------|
| Day | Concentration added ($\mu\text{g/mL}$) | Concentration found ($\mu\text{g/mL}$) \pm SD | Precision (%RSD) | Accuracy (%RE) |
| 1 | 1.5 | 1.55 \pm 0.08 | 5.18 | 3.35 |
| | 2 | 2.06 \pm 0.05 | 2.24 | 2.97 |
| | 8 | 8.09 \pm 0.28 | 3.51 | 1.12 |
| | 15 | 15.18 \pm 0.55 | 3.62 | 1.19 |
| 2 | 1.5 | 1.57 \pm 0.18 | 11.66 | 4.88 |
| | 2 | 2.14 \pm 0.15 | 6.79 | 6.94 |
| | 8 | 8.43 \pm 0.47 | 5.60 | 5.32 |
| | 15 | 15.12 \pm 0.43 | 2.87 | 0.78 |
| 3 | 1.5 | 1.35 \pm 0.13 | 9.42 | -9.86 |
| | 2 | 2.08 \pm 0.16 | 7.94 | 3.89 |
| | 8 | 8.79 \pm 0.11 | 1.20 | 9.81 |
| | 15 | 14.98 \pm 0.86 | 5.73 | -0.13 |

6

Table 3
Intra-day precision and accuracy data of spectrophotometry for quantification of CFZ in ocular tissue ($n = 3$).

| Intra-day Precision and Accuracy | | | | |
|----------------------------------|--|---|------------------|----------------|
| Replication | Concentration added ($\mu\text{g/mL}$) | Concentration found ($\mu\text{g/mL}$) \pm SD | Precision (%RSD) | Accuracy (%RE) |
| 1 | 7.24 | 7.54 \pm 0.65 | 8.60 | 4.14 |
| | 10 | 9.90 \pm 0.82 | 8.32 | -1.02 |
| | 20 | 18.65 \pm 0.62 | 3.34 | -6.76 |
| | 30 | 32.45 \pm 0.73 | 1.28 | 8.16 |
| 2 | 7.24 | 7.35 \pm 0.46 | 6.21 | 1.49 |
| | 10 | 9.65 \pm 0.58 | 6.00 | -3.46 |
| | 20 | 18.96 \pm 0.61 | 3.21 | -5.18 |
| | 30 | 32.07 \pm 0.69 | 2.15 | 6.91 |
| 3 | 7.24 | 7.50 \pm 0.53 | 7.02 | 3.59 |
| | 10 | 9.85 \pm 0.67 | 6.79 | -1.52 |
| | 20 | 19.86 \pm 1.33 | 6.71 | -0.71 |
| | 30 | 31.24 \pm 2.22 | 7.10 | 4.13 |

54

3.5. Extraction recovery

The extraction recovery of CFZ from the ocular tissue matrix is summarized in Table 5. This study was performed to evaluate whether the extraction method could be applied in the determination of CFZ retained in the ocular tissue in the *ex vivo* studies. The obtained recovery values were in the range of 90.38–93.90%, with RSD values less than 15%. In some studies, regardless the values of the extraction recovery, it has been reported that RSD values of the average of the extraction recovery should be $< 15\%$ [22,23,36]. Therefore, the extraction method was found to be precise for the application in the further *ex vivo* studies.

3.6. Dilution integrity

In the analysis process, due to a low sample volume, it could result in highly concentrated samples. Accordingly, the samples with excessively high concentrations above the set calibration range might be found and should be adjusted accordingly. To bring the

6

Table 4

Intra-day precision and accuracy data of spectrophotometry for quantification of CFZ in ocular tissue (n = 3).

| Inter-day Precision and Accuracy | | | | |
|----------------------------------|--|---|------------------|----------------|
| Day | Concentration added ($\mu\text{g/mL}$) | Concentration found ($\mu\text{g/mL}$) \pm SD | Precision (%RSD) | Accuracy (%RE) |
| 1 | 7.24 | 7.48 \pm 0.41 | 5.49 | 3.35 |
| | 10 | 10.23 \pm 0.35 | 3.43 | 2.34 |
| | 20 | 18.45 \pm 1.46 | 7.94 | -7.77 |
| | 30 | 30.92 \pm 1.85 | 5.98 | 3.08 |
| 2 | 7.24 | 7.80 \pm 0.28 | 3.54 | 7.79 |
| | 10 | 9.59 \pm 0.50 | 5.26 | -4.07 |
| | 20 | 18.49 \pm 0.95 | 5.15 | -7.57 |
| | 30 | 31.80 \pm 1.71 | 5.37 | 6.00 |
| 3 | 7.24 | 7.30 \pm 0.40 | 5.45 | 0.83 |
| | 10 | 9.87 \pm 0.94 | 9.52 | -1.32 |
| | 20 | 17.80 \pm 0.79 | 4.45 | -10.98 |
| | 30 | 31.23 \pm 2.18 | 6.99 | 4.10 |

Table 5

Mean extraction recovery of CFZ in ocular tissue (n = 3).

| Concentration | %Extraction Recovery \pm SD | %RSD |
|-----------------------|-------------------------------|------|
| 4.24 $\mu\text{g/mL}$ | 90.38 \pm 1.24 | 1.37 |
| 7.5 $\mu\text{g/mL}$ | 92.51 \pm 3.33 | 3.60 |
| 15 $\mu\text{g/mL}$ | 93.90 \pm 3.77 | 4.01 |
| 24 $\mu\text{g/mL}$ | 92.08 \pm 5.45 | 5.92 |

analyte concentration within a validated concentration range and allow reanalysis of the samples, a dilution integrity test was carried out [37]. In this evaluation, all samples in the STF and porcine ocular tissues showed the dilution integrity with RSD and RE values of \pm 15%. The dilution integrity showing the RSD and RE values which were \pm 15% was found to be optimized in several analytical validation process [22,23,36]. Therefore, even though the absorbances of samples were above the absorbance of the calibration standard solution, it could be determined by the appropriate dilution.

3.7. Application of the analytical method

24

3.7.1. Drug content determination of CFZ in the thermosensitive-mucoadhesive *in situ* gel formulation

The spectrophotometer method was initially applied to determine the amount of CFZ recovered from the thermosensitive-mucoadhesive formulation. In this study, CFZ solution with a similar concentration was also determined for the drug content. As shown in Fig. 5A, the % recovery of CFZ from the thermosensitive-mucoadhesive gel was $99.19 \pm 4.04\%$, and % recovery of CFZ from the control eye drop was $99.04 \pm 2.39\%$. The ICH has recommended that the acceptable recovery percentage in the formulation product lies between 95 and 105% [38]. Therefore, it can be concluded that no intervention between each excipient with CFZ could affect the recovery of CFZ from the formulation [39].

3.7.2. *In vitro*, *ex vivo* permeation and *ex vivo* retention study of CFZ from thermosensitive-mucoadhesive gel

In the *in vitro* and *ex vivo* permeation studies, the percentage of CFZ permeated through the membrane and ocular tissue was determined [40]. For the topical treatment of the ocular cornea, the amount of drug concentration in the ocular tissue is very influential for the effectiveness of treatment for bacterial keratitis. The formulation of thermosensitive-mucoadhesive gel was developed to localize the drug in the ocular tissue with a low permeation manner. Initially, *in vitro* permeation between thermosensitive mucoadhesive *in situ* gel and control eye drop was compared. It can be seen that after 24 h, *in vitro* permeation of CFZ from the control solution was $100.77 \pm 8.048\%$ and from the thermosensitive mucoadhesive *in situ* gel was $50.67 \pm 4.12\%$ (Fig. 5B). Furthermore, using the same method, the *ex vivo* permeation study through ocular tissue of CFZ from the thermosensitive mucoadhesive gel was compared to the control solution. The percentage of permeated drugs are depicted in Fig. 5C. Based on the results, following 24 h, $99.58 \pm 10.64\%$ and $39.4 \pm 3.21\%$ of CFZ were permeated from control solution and thermosensitive mucoadhesive gel, respectively. Therefore, the formulation of CFZ into thermosensitive mucoadhesive gel was able to sustain the release of CFZ in a controlled manner.

It was important to determine the release mechanism of CFZ from the thermosensitive mucoadhesive *in situ* gel formulation *in vitro* and *ex vivo* permeation study. The release mechanism determination was performed by fitting the data result to different mathematical kinetic models [41]. The release mechanism was determined based on the correlation coefficient (R^2) value nearly to 1. Based on the result, *in vitro* and *ex vivo* studies showed the same release mechanism of CFZ from thermosensitive mucoadhesive *in situ* gel formulation (Table 6). Both studies depicted that the release mechanism followed Higuchi's model. This model indicates that the release of CFZ from the formulation was potentially caused by the gradual swelling of the polymers [42].

As mentioned previously, the main purpose of the development of this formulation was to improve the concentration of CFZ in the ocular tissue. Therefore, the *ex vivo* retention study was carried out. Fig. 5D presents the concentration of CFZ in the ocular tissue following the application of the thermosensitive mucoadhesive gel in comparison with the control solution. After the administration of




Fig. 5. Recovery percentage of CFZ from thermosensitive gel and solution (A), *in vitro* permeation profile of CFZ from thermosensitive gel in comparison with control solution (B), *ex vivo* permeation profile of CFZ from thermosensitive gel in comparison with control solution (C) and *ex vivo* retention of CFZ in ocular tissue (D). (mean \pm SD, $n = 3$).

Table 6

In vitro and *ex vivo* correlation coefficient of CFZ from thermosensitive mucoadhesive *in situ* gel formulation in different mathematic kinetic models.

| Mathematic model | Correlation Coefficient (R^2) | |
|---------------------------|-----------------------------------|----------------|
| | <i>In vitro</i> | <i>Ex vivo</i> |
| Zero Order Kinetics | 0.7043 | 0.6328 |
| First Order Kinetics | 0.8026 | 0.8026 |
| Higuchi Models | 0.8344 | 0.8344 |
| Krossmeyer – Peppas Model | 0.2271 | 0.2271 |
| Hixson – Crowell Model | 0.7330 | 0.7330 |

thermosensitive mucoadhesive formulation, the concentrations of CFZ retained were 208.76 ± 62.16 $\mu\text{g/g}$ tissue, 1007.71 ± 179.83 $\mu\text{g/g}$ tissue and 1479.49 ± 284.12 $\mu\text{g/g}$ tissue after 1 h, 6 h and 24 h. On the other hand, in the control solution group, significant lower ($p < 0.05$) concentrations of CFZ were observed. After 1 h and 6 h, only 384.82 ± 56.99 $\mu\text{g/g}$ tissue and 245.21 ± 60.78 $\mu\text{g/g}$ tissue of CFZ were localized in the ocular tissue. Furthermore, no CFZ was detected after 24 h. Thus, thermosensitive mucoadhesive *in situ* gel formulation could increase the retention of CFZ in the ocular tissue and would potentially make the therapy more effective. Moving forward, further study involving *in vivo* studies with appropriate analytical methods must be conducted.

4. Conclusion

The present study showed the development of validation of the analytical method of CFZ in the *in vitro* and *ex vivo* evaluation steps of the formulation of thermosensitive mucoadhesive *in situ* gel. The method was developed in the simulated tear fluid (STF) and ocular tissue. The analytical method developed in this study was based on the spectrophotometry method, showing excellent linearity with

correlation coefficient values of 0.9997 in the STF and 0.9981 in ocular tissue. Furthermore, the inter-day and intra-day precision and accuracy values were not more than 15%, indicating that the method was precise and accurate. Finally, our accurate and precise method was applied to determine CFZ in the drug content determination, the *in vitro* and *ex vivo* permeation study, as well as *ex vivo* retention study from thermosensitive mucoadhesive *in situ* gel formulation.

Declaration of competing interest

The authors declare no conflicts of interest.

Author's Role

Alhidayah: Conceptualization; Data curation; Investigation; Methodology; Project administration; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing, **Muh. Al Fiqri:** Conceptualization; Methodology; Software; Validation; Visualization; Writing - review & editing, **Nirmayanti:** Methodology; Validation; Visualization, **Ummu Athiyah:** Methodology; Validation; Visualization, **Tamara Gabriela Angeleve Fadjar:** Methodology; Validation; Visualization, **Firzan Nainu:** Writing - review & editing, **Andi Arjuna:** Writing - review & editing, **Andi Dian Permana:** Conceptualization; Funding acquisition; Project administration; Supervision; Writing - review & editing.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgement

The authors wish to thank Student Creativity Program (PKM), Directorate General of Higher Education, Ministry of Education and Culture of Indonesia for funding this research.

References

- [1] L. Ung, N.R. Acharya, T. Agarwal, E.C. Alfonso, B. Bagga, P.J.M. Bispo, M.J. Burton, J.K.G. Dart, T. Doan, S.M.J. Fleiszig, P. Garg, M.S. Gilmore, D.C. Gritz, L. D. Hazlett, A. Iovieno, V. Jhanji, J.H. Kempen, C.S. Lee, T.M. Lietman, T.P. Margolis, S.D. McLeod, J.S. Mehta, D. Miller, E. Pearlman, L. Prajna, N. Venkatesh Prajna, G.D. Seitzman, S.S. Shanbhag, N. Sharma, S. Sharma, M. Srinivasan, F. Stapleton, D.T.H. Tan, R. Tandon, H.R. Taylor, E.Y. Tu, S.S. Tuli, R.B. Vajpayee, R. N. Van Gelder, S.L. Watson, M.E. Zegans, J. Chodosh, Infectious corneal ulceration: a proposal for neglected tropical disease status, *Bull. World Health Organ.* 97 (2019) 854–856, <https://doi.org/10.2471/BLT.19.232660>.
- [2] L. Ung, P.J.M. Bispo, S.S. Shanbhag, M.S. Gilmore, J. Chodosh, The persistent dilemma of microbial keratitis: global burden, diagnosis, and antimicrobial resistance, *Surv. Ophthalmol.* 64 (2019) 255–271, <https://doi.org/10.1016/j.survophthal.2018.12.003>.
- [3] D.S.J. Ting, C.S. Ho, R. Deshmukh, D.G. Said, H.S. Dua, Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance, *Eye* 35 (2021) 1084–1101, <https://doi.org/10.1038/s41433-020-01339-3>.
- [4] S.M.J. Fleiszig, A.R. Kroken, V. Nieto, M.R. Grosser, S.J. Wan, M.M.E. Metruccio, D.J. Evans, Contact lens-related corneal infection: intrinsic resistance and its compromise, *Prog. Retin. Eye Res.* 76 (2020), 100804, <https://doi.org/10.1016/j.preteyeres.2019.100804>.
- [5] A. Austin, T. Lietman, J. Rose-Nussbaumer, Update on the management of infectious keratitis, *Ophthalmology* 124 (2017) 1678–1689, <https://doi.org/10.1016/j.ophtha.2017.05.012>.
- [6] USP-NF, U.S., *Pharmacopeia National Formulary*, 38th ed., The United States Pharmacopeial Convention, United States, 2015.
- [7] U.M. Güven, M.S. Berkman, B. Şenel, Y. Yazan, Development and *in vitro/in vivo* evaluation of thermo-sensitive *in situ* gelling systems for ocular allergy, *Brazilian J. Pharm. Sci.* 55 (2019) 1–11, <https://doi.org/10.1590/s2175-97902019000117511>.
- [8] A.D. Permana, R. Nurul, P. Layadi, A. Himawan, N. Juniarti, Q. Kurnia, E. Utomo, S. Aulia, A. Arjuna, R.F. Donnelly, Thermosensitive and mucoadhesive *in situ* ocular gel for effective local delivery and antifungal activity of itraconazole nanocrystal in the treatment of fungal keratitis, *Int. J. Pharm.* 602 (2021), 120623.
- [9] M.A. dos Santos Ramos, K.C. dos Santos, P.B. da Silva, L.G. de Toledo, G.D. Marena, C.F. Rodero, B.A.F. de Camargo, G.C. Fortunato, T.M. Bauab, M. Chorilli, Nanotechnological strategies for systemic microbial infections treatment: a review, *Int. J. Pharm.* 589 (2020), 119780, <https://doi.org/10.1016/j.ijpharm.2020.119780>.
- [10] G. Begum, T. Leigh, E. Courtie, R. Moakes, G. Butt, Z. Ahmed, S. Rauz, A. Logan, R.J. Blanch, Rapid assessment of ocular drug delivery in a novel *ex vivo* corneal model, *Sci. Rep.* (2020) 1–12, <https://doi.org/10.1038/s41598-020-68254-1>.
- [11] J.T. do P. Silva, A.C. da Silva, J.M.T. Geiss, P.H.H. de Araújo, D. Becker, L. Bracht, F.V. Leimann, E. Bona, G.P. Guerra, O.H. Gonçalves, Analytical validation of an ultraviolet-visible procedure for determining lutein concentration and application to lutein-loaded nanoparticles, *Food Chem* 230 (2017) 336–342, <https://doi.org/10.1016/j.foodchem.2017.03.059>.
- [12] M. Raffi, R. Jannah, R. Heryanto, A. Kausar, D.A. Septaningsih, UV-Vis spectroscopy and chemometrics as a tool for identification and discrimination of four *Curcuma* species, *Int. Food Res. J.* 25 (2018) 643–648.
- [13] C.P. Ferreira, F.T. Techera Antunes, I.N. Rebelo, C.A. da Silva, F.N. Vilanova, D.S. Corrêa, A.H. de Souza, Application of the UV-vis spectrophotometry method for the determination of glutamate in the cerebrospinal fluid of rats, 2020, <https://doi.org/10.1016/j.jpba.2020.113290>.
- [14] I.A. Abdallah, S.F. Hammad, A. Badair, F.R. Mansour, A green homogeneous liquid-liquid microextraction method for spectrophotometric determination of daclatasvir in human plasma, *Sustain. Chem. Pharm.* 22 (2021), 100498, <https://doi.org/10.1016/j.scp.2021.100498>.
- [15] H. Heidari, C. Mammostafaei, Spectrophotometric determination of lamotrigine in plasma samples: ultrasound-assisted emulsification-microextraction based on a hydrophobic deep eutectic solvent followed by back-extraction, *Spectrochim. Acta - Part A Mol. Biomol. Spectrosc.* 247 (2021), 119098, <https://doi.org/10.1016/j.saa.2020.119098>.
- [16] M. Mabrouk, S.F. Hammad, A.A. Abdella, F.R. Mansour, Chitosan-based molecular imprinted polymer for extraction and spectrophotometric determination of ketorolac in human plasma, *Spectrochim. Acta - Part A Mol. Biomol. Spectrosc.* 241 (2020), 118668, <https://doi.org/10.1016/j.saa.2020.118668>.
- [17] N. Khan, M. Tuzen, A new green *in situ* effervescent CO₂-table-induced switchable hydrophilicity solvent extraction method of Rhodamine B in food and soft drink samples, *J. AOAC Int.* 104 (2021) 384–388, <https://doi.org/10.1093/jaoacint/qsaa107>.
- [18] Ö. Demir, M. Tuzen, N. Altunay, M.R.A. Mogaddam, Air-assisted alkanol-based nanostructured supramolecular liquid-liquid microextraction for extraction and spectrophotometric determination of Morin in fruit and beverage samples, *Food Anal. Methods.* (2021), <https://doi.org/10.1007/s12161-021-02111-3>.

- [19] M. Tuzen, N. Altunay, A. Elik, M.R. Afshar Mogaddam, K. Katin, Experimental and theoretical investigation for the spectrophotometric determination of thiabendazole in fruit samples, *Microchem. J.* 168 (2021), 106488, <https://doi.org/10.1016/j.microc.2021.106488>.
- [20] K. Al Khateb, E.K. Ozhmukhametova, M.N. Mussin, S.K. Seilkhanov, T.K. Rakhypbekov, W.M. Lau, V.V. Khutoryanskiy, In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery, *Int. J. Pharm.* 502 (2016) 70–79, <https://doi.org/10.1016/j.ijpharm.2016.02.027>.
- [21] D. Ramadon, A.J. Courtenay, A.D. Permana, I.A. Tekko, E. McAlister, M.T.C. McCrudden, H.O. McCarthy, R.F. Donnelly, A sensitive HPLC-UV method for quantifying vancomycin in biological matrices: application to pharmacokinetic and biodistribution studies in rat plasma, skin and lymph nodes, *J. Pharm. Biomed. Anal.* 189 (2020), 113429.
- [22] A.D. Permana, E. Wahyudin, M.N. Amir Ismail, M. Raihan, Q.K. Anjani, E. Utomo, P. Layadi, R.F. Donnelly, New and sensitive HPLC-UV method for concomitant quantification of a combination of antifilaria drugs in rat plasma and organs after simultaneous oral administration, *Anal. Methods*, 13 (2021) 933–945.
- [23] A.D. Permana, I.A. Tekko, H.O. McCarthy, R.F. Donnelly, New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration, *J. Pharm. Biomed. Anal.* 170 (2019) 243–253.
- [24] S. Khan, M.U. Minhas, I.A. Tekko, R.F. Donnelly, R.R.S. Thakur, Evaluation of microneedles-assisted *in situ* depot forming poloxamer gels for sustained transdermal drug delivery, *Drug Deliv. Transl. Res.* 9 (2019) 764–782, <https://doi.org/10.1007/s13346-019-00617-2>.
- [25] S.S. Pekamwar, T.M. Kalyankar, B.V. Tambe, S.J. Wadher, Validated UV-visible spectrophotometric method for simultaneous estimation of cefixime and moxifloxacin in pharmaceutical dosage form, *J. Appl. Pharm. Sci.* 5 (2015) 037–041, <https://doi.org/10.7324/JAPS.2015.50107>.
- [26] S.S. Ulhassan, S.F.A. Zaidi, I. Tariq, M.T. Ansari, Development and validation of analytical method for losartan-copper complex using UV-Vis spectrophotometry, *Trop. J. Pharm. Res.* 12 (2013) 407–411, <https://doi.org/10.4314/tjpr.v12i3.20>.
- [27] R.K.T. Kam, M.H.M. Chan, H.T. Wong, A. Ghose, A.M. Dondorp, K. Plewes, J. Taming, Quantitation of paracetamol by liquid chromatography-mass spectrometry in human plasma in support of clinical trial, *Futur. Sci. OA.* (2018) 4, <https://doi.org/10.4155/fsoa-2018-0039>.
- [28] S.R. Pandya, M. Singh, Preparation and Characterization of Magnetic Nanoparticles and their Impact on Anticancer Drug Binding and Release Processes Moderated Through 1st Tier Dendrimer, *J. Name.* (2013).
- [29] G. Nava, E. Piñón, L. Mendoza, N. Mendoza, D. Quintanar, A. Ganem, Formulation and *in vitro*, *ex vivo* and *in vivo* evaluation of elastic liposomes for transdermal delivery of ketorolac tromethamine, *Pharmaceutics* 3 (2011) 954–970, <https://doi.org/10.3390/pharmaceutics3040954>.
- [30] S. Manchanda, Nanotechnology Reviews ' Just Accepted ' Papers, *Nanotechnol. Rev.* (2011), <https://doi.org/10.1515/ntrev-2016-0011>.
- [31] A.D. Permana, R.N. Utami, A.J. Courtenay, M.A. Manggau, R.F. Donnelly, L. Rahman, Phytosomal nanocarriers as platforms for improved delivery of natural antioxidant and photoprotective compounds in propolis: an approach for enhanced both dissolution behaviour in biorelevant media and skin retention profiles, *J. Photochem. Photobiol. B Biol.* 205 (2020), 111846.
- [32] Y.S. Chhonker, C. Edi, D.J. Murry, LC-MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study, *J. Pharm. Biomed. Anal.* 151 (2018) 84–90, <https://doi.org/10.1016/j.jpba.2017.12.037>.
- [33] S.M. Sunarić, M.S. Denić, Z.Z. Bojanić, V.V. Bojanić, HPLC method development for determination of doxycycline in human seminal fluid, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 939 (2013) 17–22, <https://doi.org/10.1016/j.jchromb.2013.08.035>.
- [34] S. Ahmed, N. Mustaan, M.A. Sheraz, S.A.A. un Nabi, I. Ahmad, Validation of a UV spectrometric method for the assay of tolfenamic acid in organic solvents, *J. Pharm.* 2015 (2015) 1–8, <https://doi.org/10.1155/2015/216249>.
- [35] ICH, Technical requirements for registration of pharmaceuticals for human use: the ICH process, 2005. <https://doi.org/10.1002/9781118532331.ch23>.
- [36] A.D. Permana, S. Stewart, J. Domínguez-Robles, M.N. Amir, M.A. Bahar, R. Donnelly, E.L. Landa, Development and validation of a high-performance liquid chromatography method for levothyroxine sodium quantification in plasma for pre-clinical evaluation of long-acting drug delivery systems, *Anal. Methods*. (2021), <https://doi.org/10.1039/d1ay01049b>.
- [37] S.W. Group, F. Toxicology, V. Methods, M. Development, V. Plan, R. Validation, P. Based, S. Requirements, C. Method, V. Experiments, C. Model, I. Studies, I. Suppression, A.V. Parameters, D. Integrity, R. Revalidation, P.V. Methods, D. Requirements, M. Validation, R. Appendix, B. Validation, E. Appendix, I. Screen, U. Validation, E. Appendix, E. Flowchart, M. Validation, E. Appendix, E. Experiments, Q. Confirmation, I.M. Appendix, E. Experiments, Q.M. This, S.W. Group, F. Toxicology, Scientific working group for forensic toxicology (SWGTOX) standard practices for method validation in forensic toxicology, *J. Anal. Toxicol.* 37 (2013) 452–474, <https://doi.org/10.1093/jat/bkt054>.
- [38] S. Walfish, A statistical perspective on the ICH Q2A and Q2B guidelines for validation of analytical methods, *BioPharm Int* 19 (2006) 28–36.
- [39] M. Attimarad, K.N. Venugopala, B.E. Aldhubaib, N. SreeHarsha, A.B. Nair, Correction: development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation (PLoS ONE (2019) 14: 9 (e0222526) DOI: 10.1371/journal.pone.0222526), *PLoS ONE* 14 (2019) 1–15, <https://doi.org/10.1371/journal.pone.0227412>.
- [40] J.R. Jørgensen, F. Yu, R. Venkatasubramanian, L.H. Nielsen, H.M. Nielsen, A. Boisen, T. Rades, A. Müllertz, *In vitro*, *ex vivo* and *in vivo* evaluation of microcontainers for oral delivery of insulin, *Pharmaceutics* 12 (2020) 1–14, <https://doi.org/10.3390/pharmaceutics12010048>.
- [41] J. Zuo, Y. Gao, N. Bou-Chacra, R. Löbenberg, Evaluation of the DDSolver software applications, *Biomed Res. Int.* 2014 (2014), <https://doi.org/10.1155/2014/204925>.
- [42] C. Mircioiu, V. Voicu, V. Anuta, A. Tudose, C. Celia, D. Paolino, M. Fresta, R. Sandulovici, I. Mircioiu, Mathematical modeling of release kinetics from supramolecular drug delivery systems, *Pharmaceutics* (2019) 11, <https://doi.org/10.3390/pharmaceutics11030140>.

ORIGINALITY REPORT

15%

SIMILARITY INDEX

10%

INTERNET SOURCES

12%

PUBLICATIONS

4%

STUDENT PAPERS

PRIMARY SOURCES

| | | |
|---|---|------|
| 1 | Submitted to Universitas Hasanuddin Student Paper | <1 % |
| 2 | BILAL YILMAZ, HALUK YASAR, ALI ASCI, YUCEL KADIOGLU. "Determination of neopterin in urine of industrial workers by HPLC", Anais da Academia Brasileira de Ciências, 2022 Publication | <1 % |
| 3 | www.tandfonline.com Internet Source | <1 % |
| 4 | academic.oup.com Internet Source | <1 % |
| 5 | www.vnfoods.vn Internet Source | <1 % |
| 6 | Loboz, K.K.. "HPLC assay for bupropion and its major metabolites in human plasma", Journal of Chromatography B, 20050905 Publication | <1 % |
| 7 | patents.google.com Internet Source | <1 % |
| 8 | pharmacia.pensoft.net Internet Source | <1 % |

| | | |
|----|---|------|
| 9 | Astrid Kaunzinger, Alwin Baumeister, Klaus Cuda, Norbert Häring et al. "Determination of 11-keto-boswellic acid in human plasma", Journal of Pharmaceutical and Biomedical Analysis, 2002 Publication | <1 % |
| 10 | Gajanand Sharma, Kanika Thakur, Kaisar Raza, O.P. Katare. "Stability kinetics of fusidic acid: Development and validation of stability indicating analytical method by employing Analytical Quality by Design approach in medicinal product(s)", Journal of Chromatography B, 2019 Publication | <1 % |
| 11 | innovareacademics.in Internet Source | <1 % |
| 12 | repository.futminna.edu.ng:8080 Internet Source | <1 % |
| 13 | www.hindawi.com Internet Source | <1 % |
| 14 | Submitted to RAK Medical and Health Sciences University Student Paper | <1 % |
| 15 | gacetasanitaria.org Internet Source | <1 % |
| 16 | ijpsr.com Internet Source | <1 % |

17 Submitted to Jawaharlal Nehru Technological University Student Paper <1 %

18 Leah N. Williamson, Michael G. Bartlett, Alvin V. Terry. "Determination of Chlorpyrifos and its Metabolites in Rat Blood Using Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry", Journal of Liquid Chromatography & Related Technologies, 2007 Publication <1 %

19 ijeei.org Internet Source <1 %

20 Submitted to University of Nottingham Student Paper <1 %

21 Submitted to University of Strathclyde Student Paper <1 %

22 mau.diva-portal.org Internet Source <1 %

23 Anugerah Yaumil Ramadhani Aziz, Nurul Afia Hasir, Nurul Bahari Putri Imran, Muhammad Firdaus Hamdan et al. "Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Albendazole from Liquid Reservoir", Journal of Biomaterials Science, Polymer Edition, 2022 Publication <1 %

24

Saman Fatima, Sarwar Beg, Mohammed Samim, Farhan J. Ahmad. "Application of chemometric approach for development and validation of high performance liquid chromatography method for estimation of ropinirole hydrochloride", Journal of Separation Science, 2019

Publication

<1 %

25

pubmed.ncbi.nlm.nih.gov

Internet Source

<1 %

26

Van-Truc Nguyen, Thi-Dieu-Hien Vo, Thanh-Binh Nguyen, Nguyen Duy Dat et al.

"Adsorption of norfloxacin from aqueous solution on biochar derived from spent coffee ground: Master variables and response surface method optimized adsorption process", Chemosphere, 2022

Publication

<1 %

27

Andi Dian Permana, Diany Elim, Putri Wulandari Resky Ananda, Hilman Syamami Zaman et al. "Enhanced and sustained transdermal delivery of primaquine from polymeric thermoresponsive hydrogels in combination with Dermarollers®", Colloids and Surfaces B: Biointerfaces, 2022

Publication

<1 %

28

Submitted to University of Iowa

Student Paper

<1 %

29 Yogini Jaiswal, Gokul Talele, Sanjay Surana. "Application of HPLC for the Simultaneous Determination of Ethamsylate and Mefenamic Acid in Bulk Drugs and Tablets", Journal of Liquid Chromatography & Related Technologies, 2007
Publication <1 %

30 chem.ubbcluj.ro
Internet Source <1 %

31 hal.sorbonne-universite.fr
Internet Source <1 %

32 Kayoko Hayashida, Taishi Higashi, Daichi Kono, Keiichi Motoyama, Koki Wada, Hidetoshi Arima. "Preparation and evaluation of cyclodextrin polypseudorotaxane with PEGylated liposome as a sustained release drug carrier", Beilstein Journal of Organic Chemistry, 2014
Publication <1 %

33 Submitted to Universiti Sains Malaysia
Student Paper <1 %

34 Submitted to University of Northumbria at Newcastle
Student Paper <1 %

35 academicworks.cuny.edu
Internet Source <1 %

36 folk.ntnu.no
Internet Source

<1 %

37

Arnaud Salvador. "Rapid Quantitation of Digoxin in Human Plasma and Urine Using Isotope Dilution Liquid Chromatography - Tandem Mass Spectrometry", Journal of Liquid Chromatography & Related Technologies, 6/1/2006

Publication

<1 %

38

Shou-Mei Wu, Hsin-Lung Wu, Wei-Kung Ko, Su-Hwei Chen. "Determination of amitriptyline and nortriptyline in spiked plasma by capillary zone electrophoresis with β -cyclodextrin", Analytica Chimica Acta, 2000

Publication

<1 %

39

Submitted to Universiti Kebangsaan Malaysia

Student Paper

<1 %

40

sure.su.ac.th

Internet Source

<1 %

41

www.science.gov

Internet Source

<1 %

42

C Souppart, N Gauducheau, N Sandrenan, F Richard. "Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human

<1 %

plasma", Journal of Chromatography B,
2002

Publication

43

Charles C. Lin, Bogdan K. Matuszewski,
JoAnn Zagrobelny, Michael R. Dobrinska.
"Picogram Determination of an Avermectin
Analog in Dog Plasma by High-Performance
Liquid Chromatography with Fluorescence
Detection", Journal of Liquid
Chromatography & Related Technologies,
2006

Publication

<1 %

44

Mikio Ishii, Masahiko Sato, Masayuki
Ogawa, Takatoshi Takubo, Ken - ichi Hara,
Yasuyuki Ishii. "Simultaneous Determination
of Omeprazole and its Metabolites (5' -
Hydroxyomeprazole and Omeprazole
Sulfone) in Human Plasma by Liquid
Chromatography - Tandem Mass
Spectrometry", Journal of Liquid
Chromatography & Related Technologies,
2007

Publication

<1 %

45

centaur.reading.ac.uk

Internet Source

<1 %

46

cmjournal.biomedcentral.com

Internet Source

<1 %

47

downloads.hindawi.com

Internet Source

<1 %

- | | | |
|----|--|------|
| 48 | etd.auburn.edu Internet Source | <1 % |
| 49 | worldwidescience.org Internet Source | <1 % |
| 50 | www.dovepress.com Internet Source | <1 % |
| 51 | Arya Kadukkattil Ramanunny, Sheetu Wadhwa, Monica Gulati, Saurabh Gupta et al. "Development and validation of RP-HPLC method for 1'-Acetoxychavicol acetate (ACA) and its application in optimizing the yield of ACA during its isolation from <i>Alpinia galanga</i> extract as well as its quantification in nanoemulsion", <i>South African Journal of Botany</i> , 2021 Publication | <1 % |
| 52 | Eunmi Ban, Mijung Park, Seonghee Jeong, Taekhyun Kwon, Eun-Hee Kim, Kiwon Jung, Aeri Kim. "Poloxamer-Based Thermoreversible Gel for Topical Delivery of Emodin: Influence of P407 and P188 on Solubility of Emodin and Its Application in Cellular Activity Screening", <i>Molecules</i> , 2017 Publication | <1 % |
| 53 | Lalit K. Vora, Kurtis Moffatt, Ismaiel A. Tekko, Alejandro J. Paredes et al. "Microneedle array systems for long-acting drug delivery", <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021 | <1 % |

54 Li, X.. "Liquid chromatography/tandem mass spectrometry for the determination of magnesium lithospermate B in beagle dog serum", *Journal of Pharmaceutical and Biomedical Analysis*, 20050601

Publication

55 Nayak, Amit Kumar, and Dilipkumar Pal. "Formulation optimization and evaluation of jackfruit seed starch–alginate mucoadhesive beads of metformin HCl", *International Journal of Biological Macromolecules*, 2013.

Publication

56 Raheleh Ahmadi, Ghasem Kazemi, Amir M. Ramezani, Afsaneh Safavi. "Shaker-assisted liquid-liquid microextraction of methylene blue using deep eutectic solvent followed by back-extraction and spectrophotometric determination", *Microchemical Journal*, 2018

Publication

57 T. Imai, S. Kimura, Y. Imamura, K. Uchiyama, T. Iijima, W. J. Underberg, M. Otagiri. "Quantitation of Meclizine Dihydrochloride in Serum by Reversed Phase Ion Pair High Performance Liquid Chromatography", *Journal of Liquid Chromatography*, 1987

Publication

58 Vali, A.M.. "Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation

of the lactone and carboxylate forms of topotecan in human plasma", Journal of Chromatography B, 20050425

Publication

59 Xiangkun Yang, Xian Wu, Kyle A. Brown, Thao Le, Steven L. Stice, Michael G. Bartlett. "Determination of chlorpyrifos and its metabolites in cells and culture media by liquid chromatography-electrospray ionization tandem mass spectrometry", Journal of Chromatography B, 2017 <1 %
Publication

60 dergipark.org.tr <1 %
Internet Source

61 docplayer.net <1 %
Internet Source

62 dspace.cuni.cz <1 %
Internet Source

63 ijcrr.com <1 %
Internet Source

64 uhra.herts.ac.uk <1 %
Internet Source

65 www.ijpsonline.com <1 %
Internet Source

66 Kamal M. Matar, Mohammed E. Abdel - Hamid. "Quantification of Vigabatrin in Human Plasma by Liquid Chromatography-Electrospray Tandem Mass Spectrometry", <1 %

67

Marwa A. Hasby Saad, Haidy S.M. Khalil.
"Biofilm testing of microbiota: An essential step during corneal scrap examination in Egyptian acanthamoebic keratitis cases",
Parasitology International, 2018

<1 %

Publication

Exclude quotes Off

Exclude matches Off

Exclude bibliography On